The role of intravenous iron in anemia management and transfusion avoidance. (avaa uuden ikkunan)

Auerbach M, Goodnough LT, Picard D, Maniatis A.

Lähde‎: Transfusion 2008;48(5):988-1000.

Arkistoitu‎: PubMed 18346021

DOI‎: 10.1111/j.1537-2995.2007.01633.x

https://www.ncbi.nlm.nih.gov/pubmed/18346021 (avaa uuden ikkunan)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (avaa uuden ikkunan)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Lähde‎: BJU Int 2011;108(10):1582-7.

Arkistoitu‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (avaa uuden ikkunan)

The preoperative use of erythropoietin stimulating proteins prior to radical prostatectomy is not associated with increased cardiovascular or thromboembolic morbidity or mortality. (avaa uuden ikkunan)

Lepor H, Lipkin M, Slova D.

Lähde‎: Urology 2010;75(6):1424-8.

Arkistoitu‎: PubMed 20513505

DOI‎: 10.1016/j.urology.2009.06.095

https://www.ncbi.nlm.nih.gov/pubmed/20513505 (avaa uuden ikkunan)

Comparison of two different doses of preoperative recombinant erythropoietin in men undergoing radical retropubic prostatectomy. (avaa uuden ikkunan)

Nieder AM, Rosenblum N, Lepor H.

Lähde‎: Urology 2001;57(4):737-41.

Arkistoitu‎: PubMed 11306393

https://www.ncbi.nlm.nih.gov/pubmed/11306393 (avaa uuden ikkunan)